Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects

Study identifier:DC-990-0165

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment with Higher Doses of Quetiapine Fumarate (Seroquel®) greater than 800 mg/day in Schizophrenic or Schizoaffective Subjects.

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

No

Study drug

Quetiapine

Sex

All

Actual Enrollment

330

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Oct 2003
Primary Completion Date: -
Study Completion Date: 01 Sept 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2009 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria